{
    "organizations": [],
    "uuid": "50e310bd370d7cb7631cde5a40ef939f4933c316",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-promore-pharma-regains-rights-for/brief-promore-pharma-regains-rights-for-pxl01-manufacturing-idUSFWN1Q50F1",
    "ord_in_thread": 0,
    "title": "BRIEF-Promore Pharma Regains Rights For Pxl01 Manufacturing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - PROMORE PHARMA AB:\n* PROMORE PHARMA REGAINS RIGHTS FOR PXL01 MANUFACTURING * WILL ASSUME RESPONSIBILITY FOR MANUFACTURING OF INVESTIGATIONAL MEDICINAL PRODUCT FOR CLINICAL PHASE III TRIAL FOR PXL01 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-15T15:38:00.000+02:00",
    "crawled": "2018-02-16T16:48:56.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "promore",
        "pharma",
        "ab",
        "promore",
        "pharma",
        "regains",
        "right",
        "pxl01",
        "manufacturing",
        "assume",
        "responsibility",
        "manufacturing",
        "investigational",
        "medicinal",
        "product",
        "clinical",
        "phase",
        "iii",
        "trial",
        "pxl01",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}